Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
About this episode
Daniel Chen discusses objective-driven protein engineering and the SYNTHBODY platform for drug discovery.
May 12, 2026 | When it comes to drug discovery, either you find a rare, clean target and everything clicks, or you spend a decade chasing biology that refuses to cooperate. Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, makes the case for a different playbook: objective-driven protein engineering, where we start with the outcome and design biologics that can execute it with built-in logic. With host Andrew Bradbury, Chen unpacks the SYNTHBODY platform and what “multi-tier ...
Topics covered
- drug discovery
- protein engineering
- biologics
- SYNTHBODY platform
- multi-target drugs
- logic gating
More episodes of The Chain: Protein Engineering Podcast
- Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement
- Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?
- Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research
- Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity
- Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs
- Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability
Explore listener stats, chart rankings, contacts and more on the The Chain: Protein Engineering Podcast podcast page.